艾可瑞妥单抗(Epcoritamab) - 药物靶点：CD20 x CD3_在研适应症：大B细胞淋巴瘤，复发性 3b 级滤泡性淋巴瘤，纵隔大b细胞淋巴瘤_专利_临床

概要

基本信息

药物类型

双特异性T细胞结合器

别名

Anti-CD3 anti-CD20 bispecific antibody、Anti-CD3 anti-CD20 bispecific antibody(Genmab A/S)、epcoritamab-bysp

+ [7]

靶点

CD20 x CD3

作用方式

抑制剂、刺激剂

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、CD3刺激剂(T细胞表面糖蛋白CD3复合体刺激剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [3]

在研适应症

大B细胞淋巴瘤复发性 3b 级滤泡性淋巴瘤纵隔大b细胞淋巴瘤+ [38]

非在研适应症-

原研机构

Genmab A/S

在研机构

AbbVie, Inc.Genmab, Inc.

Genmab A/S

+ [4]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2023-05-19),

弥漫性大B细胞淋巴瘤高级别B细胞淋巴瘤

最高研发阶段(中国)申请上市

特殊审评优先审评 (美国)、突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (澳大利亚)、附条件批准 (欧盟)

登录后查看时间轴

结构/序列

Sequence Code 143818L

来源: *****

Sequence Code 319323760L

来源: *****

Sequence Code 319323796H

来源: *****

Sequence Code 616714422H

来源: *****

关联

49

项与艾可瑞妥单抗相关的临床试验

NCT06905509

/ Not yet recruiting临床2期IIT

A Phase 2 Study of Epcoritamab (Epco) Plus Physician's Choice of Platinum-Containing Chemotherapy Pre-Autologous Hematopoietic Cell Transplantation (AutoHCT) Followed by Post-AutoHCT Epco Consolidation/ Maintenance in Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL)

This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide [RICE], rituximab, cytarabine, dexamethasone, oxaliplatin or carboplatin RDHAP/X] or gemcitabine and oxaliplatin [Gem/Ox]) and autologous hematopoietic cell transplant (HCT) works in treating patients with large B-cell lymphoma (LBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab, a type of bispecific T-cell engager, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs, such as ifosfamide, etoposide phosphate, cytarabine, and gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. An autologous HCT is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Giving epcoritamab in combination with SOC platinum-based chemotherapy, such as RICE, RDHAP/X and Gem/Ox, and autologous HCT may kill more cancer cells in patients with relapsed or refractory LBCL.

开始日期2025-08-01

申办/合作机构

University of California, Davis

[+1]

NCT06811272

/ Not yet recruiting临床2期IIT

A Phase 2 Study of Outpatient Epcoritamab As Second Line Therapy in Non-Transplant Eligible Relapsed/Refractory Large B-cell Lymphoma

The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.

开始日期2025-07-16

申办/合作机构

The Massachusetts General Hospital

[+1]

NCT06796998

/ Not yet recruiting临床2期IIT

Phase 2 Trial of Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).

开始日期2025-05-01

申办/合作机构

University of Miami

[+2]

100 项与艾可瑞妥单抗相关的临床结果

登录后查看更多信息

100 项与艾可瑞妥单抗相关的转化医学

登录后查看更多信息

100 项与艾可瑞妥单抗相关的专利（医药）

登录后查看更多信息

84

项与艾可瑞妥单抗相关的文献（医药）

2025-03-29·INTERNATIONAL JOURNAL OF HEMATOLOGY

Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction.

Article

作者: Mihashi, Tatsuya ; Kai, Keita ; Kusaba, Kana ; Okamoto, Sho ; Yoshimura, Mariko ; Ando, Toshihiko ; Jinnouchi, Kazuki ; Sano, Haruhiko ; Kimura, Shinya ; Kidoguchi, Keisuke ; Katsuya, Hiroo ; Itamura, Hidekazu ; Fujita, Mai

Epcoritamab, a CD3 × CD20 bispecific antibody, has been approved as salvage therapy for patients with relapsed/refractory large B-cell lymphoma. However, immunotherapeutic agents have been linked to tumor flare reaction (TFR), which is characterized by rapid tumor proliferation associated with the immune response. This report describes the case of a 71-year-old man with relapsed/refractory diffuse large B-cell lymphoma who developed TFR in the cervical lymph nodes during treatment with epcoritamab. Prompt biopsy upon detection of tumor enlargement led to an accurate diagnosis of TFR and informed therapeutic strategies. Subsequent radiotherapy (RT) effectively controlled local lesions while preserving the systemic immune response, suggesting that RT may be an option to prevent the recurrence and progression of TFR and help to avoid discontinuation of effective therapy.

2025-02-01·COMPUTERS IN BIOLOGY AND MEDICINE

Structural insight into CD20/CD3-bispecific antibodies by molecular modeling

Article

作者: Hou, Jing-Zhou ; Chu, Xiaojie ; Sun, Ze-Yu ; Feng, Zhiwei ; Xie, Xiang-Qun ; Hou, GanQian ; Liang, Tianjian ; Li, Wei ; Zhang, Yiyang

Non-Hodgkin's Lymphoma (NHL) remains a significant challenge in hematology, with chemotherapy and radiation therapy as conventional treatment options, albeit with limitations such as adverse effects. Immunotherapy, particularly bispecific antibodies (BsAbs) T cell engagers (TCEs), has emerged as a promising approach. Despite their potential, TCEs pose challenges, including adverse events like cytokine release syndrome. Understanding the structural details of TCEs and their interactions with target proteins is crucial for optimizing their therapeutic efficacy and toxicity. In this study, we further developed our protocol MCCS-Docker for protein-protein interactions and applied it to investigate the structural intricacies of CD3 interactions with therapeutic antibodies such as OKT3, UCHT1, Mosunetuzumab, Odronextumab, Glofitamab, and Epcoritamab using computational modeling techniques. Our analysis not only approved the effectiveness of our updated MCCS-Docker protocol but also revealed detailed binding interactions between the BsAbs and CD3, elucidating key residues of Tyrosine and Asparagine in the antibodies involved in the binding interface. Molecular dynamics simulations validated the stability of these interactions over time, confirming the reliability of the binding poses generated from docking studies. Overall, our study offered a novel method to predict critical residues in protein-protein interactions and enhanced the understanding of the structural determinants governing BsAb interactions with target proteins, offering valuable insights for designing and optimizing immunotherapeutic agents for NHL and related hematologic malignancies.

2025-01-01·Journal for ImmunoTherapy of Cancer

Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma

Article

作者: Huber, Wolfgang ; Kauer, Joseph ; Müller-Tidow, Carsten ; Brinkmann, Berit ; Kolbe, Clara ; Dietrich, Sascha ; Roider, Tobias ; Dreger, Peter

Bispecific antibodies (BsAb) have emerged as a leading treatment modality in patients suffering from B-cell non-Hodgkin’s lymphoma (B-NHL). However, treatment failure is common and may potentially be attributed to pre-existing or emerging T-cell exhaustion. CD39 catalyzes—together with CD73—the hydrolysis of immunogenic ATP into immunosuppressive adenosine and thus actively promotes an immunosuppressive micromilieu. Previously, we and others demonstrated that CD39+T-cell subsets may have an adverse impact on the efficacy of T-cell-engaging immunotherapies. In this study, we applied an autologous ex vivo culture model of primary lymph node-derived T cells to investigate the potential of anti-CD39 or anti-CD73 blocking antibodies as T-cell enhancing combination partners of an anti-CD20 BsAb. Existing single-cell data of patient samples examined in this study were used to detect potential biomarkers predicting combination benefits. Combining anti-CD20 BsAb with anti-CD39 or anti-CD73 blocking antibodies induced synergistic effects on tumor cell killing, T-cell expansion and secretion of cytokines, including granzyme B, perforin, interleukin-10, interferon-γ, and tumor necrosis factor-α. We discovered that blockade of the CD39/CD73 pathway was particularly effective in patients with a high proportion of Programmed cell death protein 1 (PD-1)+T-cell immunoglobulin and mucin-domain containing-3 (TIM3)+exhausted T cells. Also, expression of CD39 in effector memory T cells indicated superior treatment benefit ex vivo. In summary, our study holds significant relevance as it introduces the combination of bispecific and anti-CD39 or anti-CD73 antibodies as a synergistic treatment approach in B-NHL, while also suggesting potential indicators to identify patients that might benefit from this treatment.

338

项与艾可瑞妥单抗相关的新闻（医药）

2025-03-26

·生物制药小编

有点“冤枉”的Genmab

近日，艾伯维已向美国西雅图华盛顿西区地方法院提起诉讼。诉状将Genmab A/S、普方生物以及艾伯维的前员工Han和Gavrilyuk博士列为被告。指控的核心是被告盗用了艾伯维的商业秘密，涉及使用二糖来增强ADC中药物接头的亲水性。起因艾伯维和Genmab最初在2020年达成关于三款双抗产品的合作，仅预付款就达到了7.5亿美元。其中Epcoritamab（商品名Epkinly）上市后为艾伯维贡献了卓越销售额。Genmab也获得了不菲的销售分成和里程碑付款，双方如今仍然在就该项目进行开发和销售分成。转折发生在去年5月，Genmab以18亿美元收购了ProfoundBio（普方生物），并获得了普方生物开发的rinatabart sesutecan (Rina-S)和其他ADC管线。而Rina-S这一管线正好就和Genmab的合作方艾伯维的管线Elahere存在竞争关系。 Elahere是2023年艾伯维收购ImmunoGen的产物，是首个获批的FRα-ADC。Elahere已经上市，目前主要用于治疗FRα阳性、铂耐药的晚期卵巢癌、输卵管癌或原发性腹膜癌患者。而Genmab认为Rina-S可以有潜力解决比当前标准护理服务更广泛的卵巢癌患者群体，甚至包括艾伯维的Elahere。根据目前产生的数据，有可能覆盖整个铂类耐药卵巢癌(PROC)人群，而不考虑FRα的表达。本以为买卖不成仁义在，双方之前好歹有大项目的合作，艾伯维或许可以通过更好的方式解决竞争问题。可没想到一年不到，艾伯维就已经将Genmab列为被告。艾伯维的指控靠谱吗？艾伯维声称，ProfoundBio最初未能建立可行的ADC研发管线，且“未付出必要的艰辛努力”，而是通过聘用前艾伯维科学家Julia Gavrilyuk博士获取技术捷径。诉状表示：“凭借窃取的商业秘密和机密信息，ProfoundBio扭转颓势，提交专利申请并推进临床管线，其宣称突破ADC开发挑战的‘唯一解决方案’——但是艾伯维认为使用‘已验证有效载荷的亲水性连接子’设计ADC——正是艾伯维的核心技术。” 此次被列为被告的艾伯维前员工Gavrilyuk与Tae Han博士（韩泰熙博士）曾在Stemcentrx共事，2016年该公司被艾伯维以58亿美元的天价收购后一同加入艾伯维。不过，两人在艾伯维待的时间并不长，2018年韩泰熙博士就出走，与赵柏腾，尚晓博士联合创立了ProfoundBio。2年后的2020年，Julia Gavrilyuk博士也随即离开创业，在艾伯维任职期间确实是担任连接子相关工作。诉状称韩泰熙博士明知Gavrilyuk在艾伯维的研究涉及普方生物所需的“精准ADC连接子技术”，且其与提出“在ADC连接子中使用开链糖类”创意的Stefan Munneke博士密切合作。这么看来，艾伯维试图指摘被告在2018年-2020年间犯下了商业窃密行动。艾伯维还指控韩泰熙与ProfoundBio“蓄意怂恿”Gavrilyuk泄露“糖支架ADC连接子及相关设计”。 “蓄意怂恿”的指控似乎有点重，也尚不清楚艾伯维是否掌握了相应的证据。不过从常理来判断，公司想要知道员工是否被蓄意怂恿应该是很难的，而且就算“怂恿”真的发生了，艾伯维是如何获得员工与前员工之间的个人隐私的？而Genmab被列为被告的缘由似乎也有些奇怪，诉状援引Genmab高管在收购尽职调查中的表述，称普方生物连接子技术的创新点在于“大量使用山梨醇提升亲水性"，艾伯维据此指控Genmab“明知或应知商业秘密来源却故意放任”。然而，艾伯维这一假设建立在Genmab明确知道收购普方生物可能带来的法律风险上，但是如果Genmab真的知道法律风险，那可能就不会决定收购普方生物，或者压低收购普方生物的价格了。总结总的来说，艾伯维近期对多家企业发起类似诉讼（如Adcentrx、百济神州），这次连合作方都要起诉，可能是真的认为Rina-S可能会对Elahere的销售额造成麻烦，因此才通过这种方式拖延其上市进度。参考来源： https://dvlabs.co/our-team/julia-gavrilyuk/ https://www.fiercebiotech.com/biotech/abbvie-takes-genmab-court-accusing-its-partner-being-willfully-blind-adc-trade-secret-theft

抗体药物偶联物并购引进/卖出

2025-03-24

·抗体圈

AbbVie起诉合作伙伴Genmab：一场 ADC 技术的商业机密争夺战

导语：全球医药巨头艾伯维（AbbVie）与丹麦生物技术公司基因马布（Genmab）的十年合作关系突生裂痕。艾伯维指控基因马布在收购美国生物科技公司 ProfoundBio 时，默许其窃取艾伯维的抗体药物偶联物（ADC）技术商业机密，涉及卵巢癌候选药物 Rina-S 的开发。这场诉讼不仅暴露了 ADC 领域激烈的技术竞争，更折射出跨国药企在知识产权保护上的深层博弈。一、诉讼核心：ADC 技术的 “隐形战场” 2025 年 3 月，艾伯维向美国华盛顿西区地方法院提起诉讼，指控基因马布及其子公司 ProfoundBio “系统性盗用” 其 ADC 技术商业机密。诉讼焦点指向 ProfoundBio 开发的 FRα 靶向 ADC 药物 Rina-S，以及其他未公开候选药物的关键技术。技术争议点：艾伯维声称，ProfoundBio 创始人 Tae Han 及前员工通过不正当手段获取其 ADC 技术，包括抗体工程、毒素连接子设计等核心工艺。非专利指控：值得注意的是，艾伯维未援引专利侵权，而是强调商业机密保护，暗示其技术尚未通过专利布局，或存在技术细节未公开的情况。二、合作破裂：从联合开发到法庭对峙艾伯维与基因马布的合作始于 2020 年，双方联合开发三款双特异性抗体药物，其中 Epkinly（epcoritamab）于 2024 年 6 月获批用于复发 / 难治性滤泡性淋巴瘤，成为双方合作的 “明星产品”。然而，此次诉讼或标志着合作关系的转折点。收购背景：基因马布于 2024 年 5 月以 18 亿美元收购 ProfoundBio，看中其 ADC 技术在实体瘤领域的潜力。艾伯维指控称，基因马布在收购前已知晓 ProfoundBio 的 “不当行为”，却未采取行动。影响范围：基因马布强调诉讼不涉及 Epkinly 项目，但行业分析师指出，若艾伯维胜诉，可能对其 ADC 管线造成重大打击，甚至影响双方在其他领域的合作信任。三、行业暗战：ADC 领域的 “人才与技术迁徙” 此次诉讼并非孤例，而是 ADC 领域知识产权纠纷的缩影。近年来，随着 ADC 疗法成为抗癌领域的 “新蓝海”，跨国药企与初创公司间的技术人才流动频繁，引发多起法律争端。艾伯维的 “维权模式”：2023 年 12 月，艾伯维起诉 Adcentrx Therapeutics，指控其前员工窃取抗体技术；2024 年 9 月，又起诉百济神州（BeiGene）在 BTK 抑制剂开发中盗用其商业机密。技术价值凸显：ADC 市场规模预计 2025 年突破 200 亿美元，其中 FRα 靶向药物因卵巢癌等适应症的高未满足需求，成为兵家必争之地。艾伯维的 Elahere（mirvetuximab soravtansine）作为首个获批的 FRα ADC，2024 年销售额已达 12 亿美元，而 ProfoundBio 的 Rina-S 被基因马布称为 “更具潜力的下一代产品”。四、双方回应：指控与反指控的角力艾伯维：在诉讼文件中，艾伯维直指基因马布 “纵容甚至鼓励技术盗窃”，称其行为 “破坏了生物医药行业的创新生态”。基因马布：公司发表声明 “坚决否认” 所有指控，称艾伯维 “未开发出任何基于其所谓商业机密的产品”，并计划 “积极应诉”。其 CEO Jan van de Winkel 强调：“这是艾伯维针对竞争对手的又一起诉讼，旨在遏制创新。” 行业观察：部分分析师认为，艾伯维可能通过诉讼迫使基因马布在合作条款上让步，或延缓竞争对手的研发进度。而基因马布若败诉，可能面临高额赔偿及技术禁令。五、深层启示：知识产权保护的 “双刃剑” 这场诉讼暴露出生物医药行业的两大痛点：技术机密的脆弱性：ADC 技术依赖高度专业化的工艺，关键人才的流动可能导致技术泄露。合作信任的危机：跨国药企与生物技术公司的联盟常以知识产权共享为基础，但利益分配与技术归属争议频发。 “这反映了 ADC 领域竞争的白热化。” 投行 Jefferies 分析师指出，“企业既要吸引顶尖人才，又要防止技术外流，这需要更完善的保密协议与竞业限制条款。” 结语艾伯维与基因马布的诉讼不仅关乎两家公司的利益，更将重塑 ADC 领域的竞争规则。随着技术壁垒的不断加高，如何在创新与合规间找到平衡，已成为全球生物医药行业共同面临的挑战。而这场法庭上的 “技术对决”，或将为行业知识产权保护写下新的注脚。参考来源：https://www.biospace.com/business/abbvie-lawsuit-alleges-that-partner-genmab-misappropriated-trade-secrets 识别微信二维码，添加抗体圈小编，符合条件者即可加入抗体圈微信群！请注明：姓名+研究方向！本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

抗体药物偶联物并购引进/卖出专利侵权

2025-03-24

·Endpoints

AbbVie files trade secrets suit against ADC competitor

AbbVie has accused a Genmab subsidiary of stealing trade secrets to build a potential competitor to its ovarian cancer treatment Elahere. In a lawsuit filed on Friday in Washington federal court, AbbVie alleged that ProfoundBio used proprietary information from a former AbbVie scientist to develop its antibody-drug conjugate pipeline. AbbVie added in its complaint that when Genmab acquired ProfoundBio for $1.8 billion last May, it gained the rights to “ProfoundBio’s technology, patents, and ADC pipeline that directly stem from its theft of AbbVie’s hard-earned trade secrets and confidential information.” A focal point of Genmab’s acquisition was rinatabart sesutecan, a candidate that’s now in Phase 2 and could compete directly with AbbVie’s ovarian cancer treatment Elahere. AbbVie’s allegations pertain to certain features of linkers, which are used in ADCs to attach an antibody to a cancer-killing payload. AbbVie argued in its complaint that some features of rinatabart sesutecan were “copied atom-for-atom.” Genmab said in a statement on Saturday that it “categorically refutes these allegations and will vigorously defend the company against AbbVie’s claims.” The company added that its separate collaboration with AbbVie on the blood cancer drug Epkinly is “unaffected.” Pharma companies have filed a raft of lawsuits alleging the misappropriation of trade secrets in recent years, including multiple cases by AbbVie.

并购抗体药物偶联物临床2期

100 项与艾可瑞妥单抗相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
大B细胞淋巴瘤	加拿大	AbbVie, Inc.	2023-10-13
复发性 3b 级滤泡性淋巴瘤	加拿大	AbbVie, Inc.	2023-10-13
纵隔大b细胞淋巴瘤	日本	Genmab A/S	2023-09-25
复发性滤泡性淋巴瘤	日本	Genmab A/S	2023-09-25
难治性滤泡性淋巴瘤	日本	Genmab A/S	2023-09-25
复发性弥漫性大B细胞淋巴瘤	欧盟	AbbVie Deutschland GmbH & Co. KG	2023-09-22
复发性弥漫性大B细胞淋巴瘤	冰岛	AbbVie Deutschland GmbH & Co. KG	2023-09-22
复发性弥漫性大B细胞淋巴瘤	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2023-09-22
复发性弥漫性大B细胞淋巴瘤	挪威	AbbVie Deutschland GmbH & Co. KG	2023-09-22
难治性弥漫性大 B 细胞淋巴瘤	欧盟	AbbVie Deutschland GmbH & Co. KG	2023-09-22
难治性弥漫性大 B 细胞淋巴瘤	冰岛	AbbVie Deutschland GmbH & Co. KG	2023-09-22
难治性弥漫性大 B 细胞淋巴瘤	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2023-09-22
难治性弥漫性大 B 细胞淋巴瘤	挪威	AbbVie Deutschland GmbH & Co. KG	2023-09-22
弥漫性大B细胞淋巴瘤	美国	Genmab, Inc.	2023-05-19
高级别B细胞淋巴瘤	美国	Genmab, Inc.	2023-05-19

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性 3a 级滤泡性淋巴瘤	临床3期	美国	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	中国	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	日本	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	澳大利亚	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	比利时	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	保加利亚	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	克罗地亚	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	捷克	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	丹麦	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	法国	Genmab A/S	2024-02-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05660967 (EPCORE DLBCL-3, ASH2024) 人工标引	临床2期	大B细胞淋巴瘤一线	44	Epcoritamab SC (arm A)	淵網繭夢鬱鹽窪獵製醖(觸網顧製壓鹹遞願鑰膚) = 膚艱壓積壓憲遞築壓獵窪構範鏇顧蓋網鑰遞鬱 (夢齋餘醖蓋衊願壓繭鹹 ) 更多	积极	2024-12-09
NCT04623541 (ASH2024) 人工标引	临床1/2期	慢性淋巴细胞白血病	40	Epcoritamab (expansion cohort (EXP))	構壓窪簾廠鏇鬱簾簾積(壓蓋齋鏇繭醖淵餘繭範) = 憲鹽獵壓鏇獵夢網鹽觸夢鏇憲鑰鹹構顧觸淵糧 (餘願壓餘獵遞築簾遞鹹 ) 更多	积极	2024-12-09
NCT04623541 (ASH2024) 人工标引	临床1/2期	慢性淋巴细胞白血病	40	Epcoritamab (TP53 aberrations)	構壓窪簾廠鏇鬱簾簾積(壓蓋齋鏇繭醖淵餘繭範) = 壓積艱膚蓋憲遞窪鬱顧夢鏇憲鑰鹹構顧觸淵糧 (餘願壓餘獵遞築簾遞鹹 ) 更多	积极	2024-12-09
ASH2024	N/A	大B细胞淋巴瘤	-	Epcoritamab monotherapy	範鬱鑰積夢鹽蓋鬱糧襯(壓網構襯鑰鬱鏇積鏇蓋) = 51% (32% G1, 16% G2, 3% G3) 範觸積餘顧願膚鹽齋餘 (襯夢繭壓簾醖夢壓鬱繭 ) 更多	-	2024-12-09
ASH2024	N/A	复发性弥漫性大B细胞淋巴瘤	-	Epcoritamab + Lenalidomide	憲觸淵鹽鏇願襯積醖觸(壓構鑰齋積製繭襯衊淵) = grade 3-4 treatment-emergent adverse events (TEAEs) were CRS (10%) 範遞糧夢膚襯襯構簾糧 (艱選衊網夢觸選築齋夢 ) 更多	-	2024-12-08
ASH2024	N/A	弥漫性大B细胞淋巴瘤	-	Epcoritamab	醖遞夢繭淵範夢膚窪積(餘願簾壓願獵蓋觸鹹糧) = 製壓夢糧憲窪鬱廠糧獵夢繭夢淵壓艱構顧廠淵 (憲築衊鏇蓋築鹽衊醖獵, 42.1 ~ 75.2) 更多	-	2024-12-08
ASH2024	N/A	弥漫性大B细胞淋巴瘤	-	Bendamustine	醖遞夢繭淵範夢膚窪積(餘願簾壓願獵蓋觸鹹糧) = 鬱鏇衊艱蓋淵鬱齋築獵夢繭夢淵壓艱構顧廠淵 (憲築衊鏇蓋築鹽衊醖獵, 52.6 ~ 72.1) 更多	-	2024-12-08
ASH2024	N/A	-	-	Epcoritamab + R-CHOP	鏇醖鏇醖淵襯構糧鬱憲(鹽觸網襯簾醖廠鹹鏇壓) = 60% 簾鑰齋顧鹽獵繭積夢鏇 (淵繭築淵鹹選製艱簾鹽 ) 更多	-	2024-12-08
ASH2024	N/A	弥漫性大B细胞淋巴瘤	-	Epcoritamab 48 mg + R-mini-CHOP	夢餘膚構鑰鑰廠艱鹹積(膚膚獵選築顧製淵鹹鏇) = All CRS events were low grade (25% grade 1, 29% grade 2), and most events were observed after the first full dose of epcoritamab. All CRS events resolved, and 1 pt (4%) discontinued epcoritamab due to CRS. No ICANS or clinical tumor lysis syndrome events were reported. 顧願膚製構憲繭蓋網觸 (顧顧夢獵築醖顧憲膚遞 ) 更多	-	2024-12-08
NCT04663347 (EPCORE NHL-2, ASH2024) 人工标引	临床1/2期	滤泡性淋巴瘤二线 \| 末线 \| 三线	111	Epcoritamab + rituximab + lenalidomide (R2)	簾簾夢鹹築選積選觸鹹(膚選窪鹹襯獵範鏇鹽選) = 願壓壓鬱築築範觸糧醖繭夢淵鹹網顧積鬱餘積 (艱憲遞憲製齋網襯壓餘 ) 更多	积极	2024-12-07
NCT04663347 (EPCORE NHL-2, ASH2024) 人工标引	临床1/2期	滤泡性淋巴瘤一线	25	Epcoritamab + Bendamustine + Rituximab	鬱壓製壓獵齋齋淵憲糧(選願繭築襯餘鏇選顧製) = 鹹蓋構範顧憲膚鹹壓鏇餘遞衊獵選窪廠糧衊廠 (願憲餘鏇糧願積壓廠繭 ) 更多	积极	2024-12-07
ASH2024	N/A	大B细胞淋巴瘤	-	Epcoritamab SC	選鹽窪蓋廠糧製選構襯(觸積夢積鑰築鑰糧鹽襯) = CRS events were mostly grade 1 (33%) or grade 2 (23%); 4% of pts had grade 3 CRS. CRS was most common following the first full (cycle 1 day 15) dose (median time to onset, 20 h). CRS resolved in all but 2 pts and led to treatment discontinuation in 1 pt 鑰鏇廠衊淵簾製鬱繭艱 (餘遞鑰壓鏇繭壓餘齋顧 ) 更多	-	2024-12-07